Author: Maxine Wright

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of a draft position statement:

• Prescribing of branded generic medication

Comments are welcomed from across the system, including residents and patients of the NENC.

This consultation will run for four weeks and close at 5pm on Tuesday 12th December 2023. Take part by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of a draft guideline:

• Self-Monitoring of Blood Glucose and Ketones in Diabetes

Comments are welcomed from across the system, including residents and patients of the NENC.

This consultation will run for four weeks and close at 5pm on Tuesday 12th December 2023. Take part by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of a draft guideline:

• Finerenone for treating chronic kidney disease in people with type 2 diabetes

Comments are welcomed from across the system, including residents and patients of the NENC.

This consultation will run for four weeks and close at 5pm on Tuesday 12th December 2023. Take part by visiting the consultations page.

North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of the proposed formulary amendments in a new consultation, covering NICE Technology Appraisals and other relevant guidance and alerts published in October 2023

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC. These consultations will run for four weeks and close at 5pm on Tuesday 12th December 2023. Take part by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA920 & TA927: Tofacitinib for active Ankylosing Spondylitis & Glofitamab for B-cell lymphoma, as outlined in the consultation document.

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.

This consultation will run for two weeks and closes at 5pm on Thursday 2nd November 2023. Take part by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on two new consultations:

• adoption of the proposed formulary amendments in a new consultation, covering NICE Technology Appraisals and other relevant guidance and alerts published in September 2023
• draft decisions made by the NENC formulary group at their meeting in September 2023

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC. These consultations will run for four weeks and close at 5pm on Tuesday 7th November 2023. Take part by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of the proposed formulary amendments in a new consultation.

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.

This consultation will run for four weeks and closes at 5pm on Wednesday 5th July 2023. Take part by visiting the consultations page.

The draft menopause guidance under consultation has been updated with the following changes:

•             Reinstating Tibolone on the list of CCHRT (this had dropped off unintentionally)

•             Reinstating the time to effect for testosterone (this had also been removed unintentionally)

•             Standardised use of levonorgestrel-IUD instead of IUS throughout the document (as per FSRH guidance)

•             Further advice about long cycle HRT (Tridestra)

•             Text colour change (from red to black)

Comments already received will be retained, and stakeholders are invited to make additional submissions if the update changes their comments.

The updated draft is available by visiting the consultations page.

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of the proposed menopause guidance in a new consultation.

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.

This consultation will run for four weeks and closes at 5pm on Tuesday 13th June 2023. Take part by visiting the consultations page.

Update, 24th May: the draft guideline has been updated to reflect new evidence on HRT after surgery for endometriosis. The updated draft is available at the link above.